| Autor: |
Manolakopoulos, Spilios, Karatapanis, Stylianos, Elefsiniotis, Jiannis, Mathou, Nicoletta, Vlachogiannakos, Jiannis, Iliadou, Elissabet, Kougioumtzan, Anastasios, Economou, Michalis, Triantos, Christos, Tzourmakliotis, Dimitrios, Avgerinos, Alec |
| Předmět: |
|
| Zdroj: |
American Journal of Gastroenterology (Springer Nature); Jan2004, Vol. 99 Issue 1, p57-63, 7p |
| Abstrakt: |
OBJECTIVES: We have evaluated the efficacy of long-term lamivudine monotherapy in patients with decompensated HBeAg-negative/HBV-DNA positive cirrhosis.METHODS: We analyzed the clinical course and outcome of lamivudine treatment in 30 consecutive cirrhotics and compared with 30 HBV untreated historical HBeAg-negative controls matched for age and gender.RESULTS: Significant clinical improvement, defined as a reduction of at least two points in Child-Pugh score was observed in 23 of the 30 treated patients (76.6%)versusnone of the 30 patients in the control group (p<0.0001) after a mean follow-up of 20.6± 12.1(±SD) months. There were 10 deaths in the treated groupversus24 in the control group (p= 0.07). Liver-related deaths occurred in five of the eight patients soon after the development of biochemical breakthrough. Patients with clinical improvement had better survival than patients with no improvement (p= 0.04) or those who developed biochemical breakthrough due to YMDD mutants (p= 0.001).CONCLUSIONS: Lamivudine significantly improves liver function in HBeAg-negative decompensated cirrhosis. However, the development of the biochemical breakthrough due to YMDD mutants is associated with fatal outcome. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
